C07D473/18

CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

SMALL MOLECULE ADAPTER REGULATED, TARGET SPECIFIC CHIMERIC ANTIGEN RECEPTOR BEARING T CELLS (SMART CARS)
20230159611 · 2023-05-25 ·

In one embodiment, the invention provides a chimeric antigen receptor (CAR) T cell which is conjugated to a bi-functional molecule which is specific for both an extracellular binding domain of the chimeric antigen receptor (CAR) T cell and prostate-specific membrane antigen (PSMA). The chimeric antigen receptor (CAR) T cell contains a T cell signaling domain and the extracellular binding domain of the chimeric antigen receptor (CAR) T cell is not specific for prostate-specific membrane antigen (PSMA). Compositions and methods of treatment using these CAR T cells are also disclosed.

HDAC INHIBITOR SOLID STATE FORMS
20230159499 · 2023-05-25 ·

The present disclosure relates to the crystalline mesylate Form 1 salt of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0 ]hex-3-yl}pyrimidine-5-carboxamide and methods of making the same. The crystalline mesylate Form 1 salt of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide is useful in preparation of pharmaceutical compositions and dosage forms for the treatment of cancer, immune disorders and inflammation.

STABILIZATION OF MHC COMPLEXES
20230111132 · 2023-04-13 ·

Provided, inter alia, are methods and compositions for treating cancer.

STABILIZATION OF MHC COMPLEXES
20230111132 · 2023-04-13 ·

Provided, inter alia, are methods and compositions for treating cancer.

BIOMIMETIC G-QUARTET COMPOUNDS

A compound of formula I:

##STR00001##

wherein A is present or absent; X1, X2, X3 and X4 are, independently from each other, an alkyl;

Y1, Y2, Y3 and Y4 are independently from each other a C1-C10 alkyl, -Z1, Z2, Z3 and Z4 are independently from each other a C1-C5 linear alkyl; R1 is a group allowing to carry out bioorthogonal reactions; and R2 is group including a N.

PHOTOPROXIMITY PROFILING OF PROTEIN-PROTEIN INTERACTIONS IN CELLS

Photoactive probes and probe systems for detecting biological interactions are described. The photoactive probes include probes that combine both photocleavable and photoreactive moieties. The photoactive probe systems can include a first probe comprising a photocatalytic group and a second probe comprising a group that can act as a substrate for the reaction catalyzed by the photocatalytic group. The probes and probe systems can also include groups that can specifically bind to a binding partner on a biological entity of interest and a detectable group or a precursor thereof. The probes and probe systems can detect spatiotemporal interactions of proteins or cells. In some embodiments, the interactions can be detected in live cells. Also described are methods of detecting the biological interactions.

PIKFYVE KINASE INHIBITORS

The present invention relates to compounds useful as inhibitors of phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) as well as their use for treating diseases and disorders associated with PIKfyve.

PIKFYVE KINASE INHIBITORS

The present invention relates to compounds useful as inhibitors of phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) as well as their use for treating diseases and disorders associated with PIKfyve.